NCT04214067: Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
- State
- Under way
- Phase
- Phase 3
- People
- 164 taking part
- Started
- 9 Apr 2020
- Primary completion
- 30 Dec 2025
- Arms
- Arm II (EBRT, brachytherapy, pembrolizumab)
- Results
- None posted
- 30 Dec 2019: Trial registered
- 9 Apr 2020: Trial started